SCHEMBL289136

SCHEMBL289136

CC[C@](C)(N)CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21690012 1.00
SCHEMBL5324328 1.00
SCHEMBL9536247 0.86 HMGCR (0.55)
SCHEMBL8382759 0.80 S1PR4 (0.45)
SCHEMBL9519196 0.80 S1PR4 (0.45)
Citric Acid SCHEMBL17375316 0.80 ALDH1A1 (0.62)
SCHEMBL25295848 0.79
SCHEMBL7341356 0.79
SCHEMBL5323906 0.79
Oxalic Acid SCHEMBL1354876 0.78 MEN1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009132861-A2 AQUEOUS, ACID BATH AND METHOD FOR THE ELECTROLYTIC DEPOSITION OF COPPER ATOTECH DEUTSCHLAND GMBH (DE) 2009-11-05 WO claimed
US-20230000996-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY 2023-01-05 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-11066416-B2 Rapafucin derivative compounds and methods of use thereof THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-20 US disclosed
WO-2021067439-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2021-04-08 WO disclosed
EP-2934563-B1 ANTIMICROBIAL COMPOUNDS, THEIR SYNTHESIS AND APPLICATIONS THEREOF JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENT RESEARCH (IN) 2020-07-08 EP disclosed
US-20200040004-A1 RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF RAPAFUSYN PHARMACEUTICALS, INC. 2020-02-06 US disclosed
EP-3110802-B1 ETHYNYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-10-10 EP disclosed
US-9725416-B2 Ethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2017-08-08 US disclosed
EP-3110802-A1 ETHYNYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-01-04 EP disclosed
US-20160362383-A1 ETHYNYL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2016-12-15 US disclosed
WO-2015128307-A1 ETHYNYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2015-09-03 WO disclosed
EP-2427475-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS Yu, Chongxi (US) 2012-03-14 EP disclosed
WO-2010127640-A1 HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS TECHFIELDS BIOCHEM CO., LTD. (CN) 2010-11-11 WO disclosed
EP-0907632-A1 INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED PHENETHYL COMPOUNDS Bayer Corporation (US) 1999-04-14 EP disclosed
WO-1997043247-A1 INHIBITION OF MATRIX METALLOPROTEASES BY SUBSTITUTED PHENETHYL COMPOUNDS BAYER CORPORATION (US) 1997-11-20 WO disclosed